Zamecnik Patrik, Israel Bas, Feuerstein Jürgen, Nagarajah James, Gotthardt Martin, Barentsz Jelle O, Hambrock Thomas
Department of Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Eur Urol Focus. 2022 Nov;8(6):1802-1808. doi: 10.1016/j.euf.2022.03.001. Epub 2022 Mar 23.
Patients with renal impairment cannot undergo angiography because iodine and gadolinium contrast agents are contraindicated. Iron-containing ultrasmall superparamagnetic iron oxide particles, such as ferumoxtran-10, are not contraindicated in these patients. Thus, patients with renal failure can still undergo angiography with ferumoxtran-10.
To evaluate the visibility of pelvic vessels with magnetic resonance angiography (MRA) using ferumoxtran-10 as contrast agent.
DESIGN, SETTING, AND PARTICIPANTS: Three hundred and eighty-one patients diagnosed with primary or recurrent prostate cancer underwent pelvic ferumoxtran-10 MRA. Eleven anatomical pelvic-vessel segments per patient were evaluated using qualitative and quantitative criteria for image quality (IQ), vessel visibility (VV), and the contrast-to-noise ratio (CNR).
Ferumoxtran-10-enhaced MRA.
IQ, VV, and CNR were assessed on a 5-point scale for each data set/vessel segment (very poor, poor, moderate, good, and excellent).
IQ was good to excellent for 98.2% of the data sets and VV was good to excellent for 97.7% of all vessel segments. The mean CNR for all segments was 88.13 (standard deviation 4.22). Contrast bolus imaging cannot be performed with this technique, so it is impossible to visualize the arterial or venous phase separately. The timing of contrast administration is also a limitation, with MRA performed 1 d after contrast infusion.
Ferumoxtran-10 MRA showed excellent image quality and visibility for pelvic vessels. In addition, the homogeneity of the intraluminal contrast was superior. Patients with preterminal or terminal renal function can benefit from ferumoxtran-10 MRA if visualization of their pelvic vessels is required.
Magnetic resonance imaging of blood vessels using a contrast agent called ferumoxtran-10 is a promising technique for patients with impaired kidney function, as it provides high-quality visualization of blood vessels in the pelvis.
肾功能不全患者无法进行血管造影,因为碘造影剂和钆造影剂对此类患者是禁忌的。含超小超顺磁性氧化铁颗粒的造影剂,如 ferumoxtran - 10,对此类患者并非禁忌。因此,肾衰竭患者仍可使用 ferumoxtran - 10 进行血管造影。
评估以 ferumoxtran - 10 为造影剂的磁共振血管造影(MRA)对盆腔血管的显影情况。
设计、地点和参与者:381 例诊断为原发性或复发性前列腺癌的患者接受了盆腔 ferumoxtran - 10 MRA 检查。采用定性和定量标准对每位患者的 11 个盆腔血管解剖节段的图像质量(IQ)、血管显影(VV)和对比噪声比(CNR)进行评估。
Ferumoxtran - 10 增强 MRA。
对每个数据集/血管节段的 IQ、VV 和 CNR 进行 5 分制评分(非常差、差、中等、好、优秀)。
98.2%的数据集 IQ 为良好至优秀,97.7%的血管节段 VV 为良好至优秀。所有节段的平均 CNR 为 88.13(标准差 4.22)。该技术无法进行造影剂团注成像,因此无法分别显示动脉期或静脉期。造影剂给药时间也是一个限制因素,MRA 在造影剂注入 1 天后进行。
Ferumoxtran - 10 MRA 对盆腔血管显示出优异的图像质量和显影效果。此外,腔内造影剂的均匀性更佳。如果需要对盆腔血管进行显影,终末期前或终末期肾功能不全的患者可从 Ferumoxtran - 10 MRA 中获益。
对于肾功能受损的患者,使用名为 ferumoxtran - 10 的造影剂进行血管磁共振成像,是一种很有前景的技术,因为它能提供高质量的盆腔血管显影。